Why your OA grade shapes the injection decision

Receiving a scan report with an OA grade can feel like being handed a verdict without a translation. In practice, that grade does far more than describe how worn your joint is — it actively shapes which injection options are worth considering, which are unlikely to help, and whether non-surgical treatment remains realistic at all.

The Kellgren-Lawrence (KL) scale is the standard radiographic framework clinicians use to make this assessment. Running from 0 (no changes) to 4 (severe bone-on-bone loss with bony deformity), it classifies knee OA from plain X-ray findings — joint-space narrowing, osteophyte burden, and subchondral sclerosis. Each grade carries a rough ceiling on what certain injectables can realistically offer: at lower grades, several options remain viable; beyond a certain threshold, the structural environment is too compromised for some treatments to hold meaningful benefit.

That ceiling is an important concept, but it is not the whole picture. Symptom duration, prior treatment, joint alignment, and broader health all carry equal weight in any genuine suitability assessment — the grade is the starting point, not the final word.

The Kellgren-Lawrence scale and what each grade signals

Produced from a weight-bearing X-ray — taken standing, so the joint carries load — the KL scale assesses four features: joint-space narrowing, osteophyte formation, subchondral sclerosis, and bony deformity. Each grade reflects a progressively worse combination of those findings.

KL 0 and I represent normal or doubtful change — possible early osteophyte formation but no clear narrowing. Injection therapy is rarely indicated at this stage; other pain drivers are more likely.

KL II marks mild OA: definite osteophytes with possible narrowing. Patients at this grade typically respond well to both corticosteroid and hyaluronic acid injections, and a combined approach is common for more sustained early-stage relief. That said, 'responds well' means a meaningful proportion benefit — not that outcomes are guaranteed for everyone.

KL III is moderate OA — multiple osteophytes, definite narrowing, and subchondral sclerosis. Both corticosteroid and hyaluronic acid injections can still be appropriate here, but the available joint space is reduced and the tissue environment less favourable, so relief windows tend to be shorter. Expectations need calibrating accordingly.

KL IV is severe, often described as 'bone-on-bone': large osteophytes, marked narrowing, dense sclerosis, and sometimes visible bony deformity. At this grade, injectables offer very limited benefit — hyaluronic acid cannot be retained in a joint with negligible space, and repeated corticosteroid use risks accelerating what tissue remains. This is where a different conversation begins: surgical planning, rather than further injection cycles, generally becomes the primary focus.

What X-ray misses — and where MRI changes the picture

Plain X-ray earns its place in OA assessment — it captures bony architecture clearly and produces the KL grade described above. What it cannot show is equally important: cartilage thickness and surface integrity, the synovial lining, subchondral bone marrow, and the menisci are all effectively invisible on plain film. Meaningful tissue damage can be present and symptomatic long before any narrowing appears on an X-ray, which means a 'normal-looking' plain film does not rule out clinically significant OA.

MRI fills these gaps. Rather than asking how much joint space remains, it asks which tissue is actually driving the pain — a distinction that directly influences which injection, if any, is appropriate.

Two MRI findings deserve brief definition. Bone marrow lesions (BMLs) are areas of abnormal signal within the subchondral bone — essentially stress-related bone oedema — that correlate closely with OA pain and progression. Synovitis refers to thickening and inflammation of the synovial lining; its presence suggests active intra-articular inflammation and may support the use of anti-inflammatory injections, with some evidence linking untreated synovitis to subsequent radiographic worsening.

A current MRI-based definition of tibiofemoral OA does not even require visible cartilage thinning: BMLs and synovitis on MRI can independently meet the diagnostic criteria. That matters clinically — it means a patient with a near-normal X-ray may still have a genuinely inflamed, symptomatic joint that responds to appropriate treatment.

Where X-ray already shows severe bone-on-bone, MRI is typically set aside; the structural case for surgical planning is already made. MRI adds most where the grade sits in the mild-to-moderate range and the question is precisely what to target.

How MRI findings guide injectable choice

Specific MRI findings don't just confirm OA is present — they point towards which biological mechanism is most active and, by extension, which injection approach may address it most directly.

When BMLs are prominent, the MOAKS system provides structured grading across 14 knee subregions on a 0–3 ordinal scale. High-grade lesions — grade 2 or 3, especially those accompanied by adjacent subchondral cysts — are considered primary candidates for intra-osseous or biologic injection approaches, and their presence predicts accelerated disease progression.

Synovitis on MRI shifts the calculus differently. Active synovial inflammation is associated with subsequent radiographic worsening when left untreated; its presence tends to support an anti-inflammatory injectable as the priority step before considering biologic or volume-restoring options.

MRI findings cannot yet drive injection selection algorithmically: most clinical guidance remains KL-grade-first, with MRI used to refine or escalate that decision. How precisely a high BML grade or low-grade synovitis should alter the choice between, say, PRP and corticosteroid still rests on specialist clinical judgement rather than a formalised protocol — which is where experienced subspecialty assessment matters most.

For patients with persistent symptoms but a near-normal conventional MRI, compositional techniques such as T2 mapping and dGEMRIC can detect proteoglycan and collagen matrix disruption before any morphological thinning is visible. These remain specialist tools rather than routine practice, but for younger or more active patients in whom preserving existing tissue is a clinical priority, they can identify an early-intervention window that standard imaging would miss.

Grade is necessary — but not sufficient

Knowing your KL grade is a useful starting point — but a grade, by itself, does not open or close the door to injection treatment. Consider a straightforward scenario: a patient with KL grade II arthritis who has not yet tried physiotherapy, does not manage their weight, and is still taking no regular anti-inflammatories. Despite a 'favourable' imaging grade, that patient would not typically be offered an injection. Conservative measures must have been genuinely attempted first, and a structured assessment checks whether they have.

The clinical picture that surrounds the grade matters just as much. Symptom duration, how previous treatments have fared, joint alignment (significant varus or valgus loading changes what any injection can realistically achieve), and comorbidities — diabetes, for instance, affects corticosteroid safety — all feed into the decision. An expert-panel review examining real-world hyaluronic acid injection scenarios found that even among specialists, fewer than half of cases were rated clearly appropriate, confirming that the decision rarely reduces to a single number.

The reverse also holds: a higher KL grade does not automatically rule out injection support. A KL III patient with active synovitis, well-managed alignment, and a completed course of physiotherapy may be a stronger candidate than a KL II patient who has bypassed conservative care entirely.

This is why a proper clinical assessment precedes any injection decision rather than the scan report serving as the trigger. The grade informs the conversation; it does not conclude it.

When imaging points toward surgery rather than injection

Reaching KL grade IV shifts the clinical conversation — but it does not predetermine where it ends. The point is not that injections are categorically refused; it is that their likely benefit is too narrow to justify further injection cycles as the primary plan. At that point, assessment typically pivots toward what comes next rather than what else can be tried first.

What that looks like depends heavily on factors specific to the individual: age, activity level, joint alignment, and — crucially — what the patient is hoping to preserve or regain. A 58-year-old with bilateral deformity and significantly restricted daily function is having a different conversation from a 71-year-old with unilateral grade IV changes and an otherwise active life. Surgical options range from joint-preserving procedures, where the remaining structure permits them, to joint replacement. MRI at this stage is often set aside — the X-ray picture is usually clear enough to move directly into planning without it.

For anyone with a KL IV result, the most useful preparation for a specialist appointment is not the grade itself, but a clear account of what specifically has become impossible, and how limiting that is day-to-day. That framing — not the scan — drives surgical timing. A structured assessment maps the grade against those functional realities and sets out what a realistic next step looks like for that particular patient.